Search Results

Sera Prognostics Inc. announced that as a result of the annual Russell Reconstitution being finalized on June 28, 2024, the Company has been added to the Russell Small-Cap 2000 and Russell 3000 indexes effective with the opening of equity markets today.

Sera Prognostics Inc., The Pregnancy Company®, focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, announced financial results for the first quarter of 2024 ended March 31, 2024.

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the fourth quarter and full year ended December 31, 2023.

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report first quarter fiscal year 2024 financial results on Wednesday, May 8, 2024, after the close of the market.

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the TD Cowen 44th Annual Healthcare Conference on Monday, March 4, 2024 at 2:50 p.m. ET.